New insights into the biology and pharmacology of the Multidrug Resistance Protein (MRP) from gene knockout models

Biochemical Pharmacology

Volumn 58, Issue 4, 1999, Pages 557-562

  Rappa, Germana ^a   Finch, Rick A ^b   Sartorelli, Alan C ^b   Lorico, Aurelio ^a  

^a OSLO UNIVERSITY HOSPITAL   (Norway)

^b YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Co transport; Etoposide; Glutathione; Knockout mice; MRP; Multidrug resistance

Indexed keywords

ETOPOSIDE; GLUTATHIONE; HEAVY METAL; LEUKOTRIENE C4; MULTIDRUG RESISTANCE PROTEIN; POTASSIUM CHANNEL;

ANIMAL CELL; ANIMAL EXPERIMENT; GLUTATHIONE METABOLISM; KNOCKOUT MOUSE; MOUSE; MULTIDRUG RESISTANCE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

EID: 0033567429     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(99)00074-X     Document Type: Note

References (58)

1. 1. Cole SPC, Bhardwaj G, Gerlach JH, Mackie JE, Grant CE, Almquist KC, Stewart AJ, Kurz EU, Duncan AMV and Deeley RG, Overexpression of a transporter gene in a multidrug resistant human lung cancer cell line. Science 258: 1650-1654, 1992.
2. 2. Lautier D, Canitrot Y, Deeley RG and Cole SPC, Multidrug resistance mediated by the multidrug resistance protein (MRP) gene. Biochem Pharmacol 52: 967-977, 1996.
3. 3. Fisher GA and Sikic BI, Clinical studies with modulators of multidrug resistance. Hematol Oncol Clin North Am 9: 363-382, 1995.
4. 4. Hanania EG and Deisseroth AB, Serial transplantation shows that early hematopoietic precursor cells are transduced by MDR-1 retroviral vector in a mouse gene therapy model. Cancer Gene Ther 1: 21-25, 1994.
5. 5. Sorrentino BP, McDonagh KT, Woods D and Orlic D, Expression of retroviral vectors containing the human multidrug resistance 1 cDNA in hematopoietic cells of transplanted mice. Blood 86: 491-501, 1995.
6. 6. D'Hondt V, Caruso M and Bank A, Retrovirus-mediated gene transfer of the multidrug resistance-associated protein (MRP) cDNA protects cells from chemotherapeutic agents. Hum Gene Ther 8: 1745-1751, 1997.
7. 7. Deisseroth AB, Kavanagh J and Champlin R, Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of ovarian cancer: A pilot trial. Hum Gene Ther 5: 1507-1522, 1994.
8. 8. Deisseroth AB, Holmes F, Hortobagyi G and Champlin R, Use of safety-modified retroviruses to introduce chemotherapy resistance sequences into normal hematopoietic cells for chemoprotection during the therapy of breast cancer: A pilot trial. Hum Gene Ther 7: 401-416, 1996.
9. 9. O'Shaughnessy JA, Cowan KH, Nienhuis AW, McDonagh KT, Sorrentino BP, Dunbar CE, Chiang Y, Wilson W, Goldspiel B, Kohler D, Cottler-Fox M, Leitman S, Gottesman M, Pastan I, Denicoff A, Noone M and Gress R, Retroviral mediated transfer of the human multidrug resistance gene (MDR-1) into hematopoietic stem cells during autologous transplantation after intensive chemotherapy for metastatic breast cancer. Hum Gene Ther 5: 891-911, 1994.
10. 10. Hesdorffer C, Antman K, Bank A, Fetell M, Mears G and Begg M, Human MDR gene transfer in patients with advanced cancer. Hum Gene Ther 5: 1151-1160, 1994.
11. 11. Aran JM, Gottesman MM and Pastan I, Construction and characterization of bicistronic retroviral vectors encoding the multidrug transporter and beta-galactosidase or green fluorescent protein. Cancer Gene Ther 5: 195-206, 1998.
12. 12. Schinkel AH, Smit JJM, van Tellingen O, Beijnen JH, Wagenaar E, van Deemter L, Mol CA, van der Valk MA, Robanus-Maandag EC, te Riele HPJ, Berns AJM and Borst P, Disruption of the mouse mdr1a P-glycoprotein gene leads to a deficiency in the blood-brain barrier and to increased sensitivity to drugs. Cell 77: 491-502, 1994.
13. 13. Schinkel AH, Mayer U, Wagenaar E, Mol CA, van Deemter L, Smit JJ, van der Valk MA, Voordouw AC, Spits H, van Tellingen O, Zijlmans JM, Fibbe WE and Borst P, Normal viability and altered pharmacokinetics in mice lacking mdr1-type (drug-transporting) P-glycoproteins. Proc Natl Acad Sci USA 94: 4028-4033, 1997.
14. 14. Borst P and Schinkel AH, What have we learnt thus far from mice with disrupted P-glycoprotein genes? Eur J Cancer 32A: 985-990, 1996.
15. 15. Nooter K, Westerman AM, Flens MJ, Zaman GJR, Scheper RJ, van Wingerden KE, Burger H, Oostrum R, Boersma T, Sonneveld P, Gratama JW, Kok T, Eggermont AMM, Bosman FT and Stoter G, Expression of the multidrug resistance-associated protein (MRP) gene in human cancers. Clin Cancer Res 1: 1301-1310, 1995.
16. 16. Stride BD, Valdimarsson G, Gerlach JH, Wilson G, Cole SPC and Deeley RG, Structure and expression of the messenger RNA encoding the murine multidrug resistance protein, an ATP-binding cassette transporter. Mol Pharmacol 49: 962-971, 1996.
17. 17. Lorico A, Rappa G, Flavell RA and Sartorelli AC, Double knockout of the MRP gene leads to increased drug sensitivity in vitro. Cancer Res 56: 5351-5355, 1996.
18. 18. Rappa G, Lorico A, Flavell RA and Sartorelli AC, Evidence that the multidrug resistance protein (MRP) functions as a co-transporter of glutathione and natural product toxins. Cancer Res 57: 5232-5237, 1997.
19. 19. Lorico A, Rappa G, Finch RA, Yang D, Flavell RA and Sartorelli AC, Disruption of the murine MRP (multidrug resistance protein) gene leads to increased sensitivity to etoposide (VP-16) and increased levels of glutathione. Cancer Res 57: 5238-5242, 1997.
20. 20. Wijnholds J, Evers R, van Leusden MR, Mol CA, Zaman GJ, Mayer U, Beijnen JH, van der Valk M, Krimpenfort P and Borst P, Increased sensitivity to anticancer drugs and decreased inflammatory response in mice lacking the multidrug resistance-associated protein. Nat Med 3: 1275-1279, 1997.
21. 21. Stride BD, Grant CE, Loe DW, Hipfner DR, Cole SPC and Deeley RG, Pharmacological characterization of the murine and human orthologs of multidrug resistance protein in transfected human embryonic kidney cells. Mol Pharmacol 52: 344-353, 1997.
22. 22. Zaman GJR, Flens MJ, van Leusden MR, de Haas M, Mülder HS, Lankelma J, Pinedo HM, Scheper RJ, Baas F, Broxterman HJ and Borst P, The human multidrug resistance-associated protein MRP is a plasma membrane drug-efflux pump. Proc Natl Acad Sci USA 91: 8822-8826, 1994.
23. 23. Grant CE, Valdimarsson G, Hipfner DR, Almquist KC, Cole SPC and Deeley RG, Overexpression of multidrug resistance-associated protein (MRP) increases resistance to natural product drugs. Cancer Res 54: 357-361, 1994.
24. 24. Breuninger LM, Paul S, Gaughan K, Miki T, Chan A, Aaronson SA and Kruh GD, Expression of multidrug resistance-associated protein in NIH/3T3 cells confers multidrug resistance associated with increased drug efflux and altered intracellular drug distribution. Cancer Res 55: 5342-5347, 1995.
25. 25. Mortensen RM, Conner DA, Chao S, Geisterfer-Lowrance AAT and Seidman JG, Production of homozygous mutant ES cells with a single targeting construct. Mol Cell Biol 12: 2391-2395, 1992.
26. 26. Zaman GJR, Versantvoort CHM, Smit JJM, Eijdems EWHM, de Haas M, Smith AJ, Broxterman HJ, Mulder HS, de Vries EGE, Baas F and Borst P, Analysis of the expression of MRP, the gene for a new putative transmembrane drug transporter, in human multidrug resistant lung cancer cell lines. Cancer Res 53: 1747-1750, 1993.
27. 27. Barrand MA, Heppell-Parton AC, Wright KA, Rabbitts PH and Twentyman PR, A 190-kilodalton protein overexpressed in non-P-glycoprotein-containing multidrug-resistance cells and its relationship to the MRP gene. J Natl Cancer Inst 86: 110-117, 1994.
28. 28. Lorico A, Rappa G, Srimatkandada S, Catapano CV, Fernandes DJ, Germino JF and Sartorelli AC, Increased rate of adenosine triphosphate-dependent etoposide (VP-16) efflux in a murine leukemia cell line overexpressing the multidrug resistance-associated protein (MRP) gene. Cancer Res 55: 4352-4360, 1995.
29. 29. Cole SPC, Sparks KE, Fraser K, Loe DW, Grant CE, Wilson GM and Deeley RG, Pharmacological characterization of multidrug resistant MRP-transfected human tumor cells. Cancer Res 54: 5902-5910, 1994.
30. 30. Braman RS and Foreback CC, Methylated forms of arsenic in the environment. Science 182: 1247-1249, 1973.
31. 31. Tripathi N and Flora SJ, Effects of some thiol chelators on enzymatic activities in blood, liver and kidneys of acute arsenic (III) exposed mice. Biomed Environ Sci 11: 38-45, 1998.
32. 32. Saleh S and Khayyal MT, Effect of cysteine on the hepatic toxicity and antischistosomial activity of antimonyl potassium tartrate. Bull World Health Organ 53: 379-384, 1976.
33. 33. Jovov B, Ismailov II and Benos DJ, Cystic fibrosis transmembrane conductance regulator is required for protein kinase A activation of an outwardly rectified anion channel purified from bovine tracheal epithelia. J Biol Chem 270: 1521-1528, 1995.
34. 34. Gabriel SE, Clarke LL, Boucher RC and Stutts MJ, CFTR and outwardly rectifying chloride channels are distinct proteins with a regulatory relationship. Nature 363: 263-266, 1993.
35. 35. Hardy SP, Goodfellow HR, Valverde MA, Gill DR, Sepulveda FV and Higgins CF, Protein kinase C-mediated phosphorylation of the human multidrug resistance P-glycoprotein regulates cell volume-activated chloride channels. EMBO J 14:68-75, 1995.
36. 36. Higgins CF, Volume-activated chloride currents associated with the multidrug resistance P-glycoprotein. J Physiol (Lond) 482: 31S-36S, 1995.
37. 37. Inagaki N, Gonoi T, Clement JP 4th, Namba N, Inazawa J, Gonzalez G, Aguilar-Bryan L, Seino S and Bryan J, Reconstitution of IKATP: An inward rectifier subunit plus the sulfonylurea receptor. Science 270: 1166-1170, 1995.
38. + channels and volume-regulated anion channels in multidrug-resistant small cell lung cancer cells. Cancer Res 53: 4156-4160, 1993.
39. 4 and structurally related conjugates. J Biol Chem 269: 27807-27810, 1994.
40. 40. Müller M, Meijer C, Zaman GJR, Borst P, Scheper RJ, Mulder NH, de Vries EGE and Jansen PLM, Overexpression of the gene encoding the multidrug resistance-associated protein results in increased ATP-dependent glutathione S-conjugate transport. Proc Natl Acad Sci USA 91: 13033-13037, 1994.
41. 41. Loe DW, Almquist KC, Cole SPC and Deeley RG, ATP-dependent 17ß-estradiol 17-(ß-D-glucuronide) transport by multidrug resistance protein (MRP). Inhibition by cholestatic steroids. J Biol Chem 271: 9683-9689, 1996.
42. 4 and chemotherapeutic agents in membrane vesicles. Demonstration of glutathione-dependent vincristine transport. J Biol Chem 271: 9675-9682, 1996.
43. 43. Jedlitschky G, Leier I, Buchholz U, Bamouin K, Kurz G and Keppler D, Transport of glutathione, glucuronate, and sulfate conjugates by the MRP gene-encoded conjugate export pump. Cancer Res 56: 988-994, 1996.
44. 44. Evers R, Cnubben NH, Wijnholds J, van Deemter L, van Bladeren PJ and Borst P, Transport of glutathione prostaglandin A conjugates by the multidrug resistance protein 1. FEBS Lett 419: 112-116, 1997.
45. 45. Leier I, Jedlitschky G, Buchholz U, Center M, Cole SPC, Deeley RG and Keppler D, ATP-dependent glutathione disulphide transport mediated by the MRP gene-encoded conjugate export pump. Biochem J 314: 433-437, 1996.
46. 46. Ishikawa T, Li ZS, Lu YP and Rea PA, The GS-X pump in plant, yeast and animal cells: Structure, function, and gene expression. Biosci Rep 17: 189-207, 1997.
47. 47. Keppler D, Konig J and Buchler M, The canalicular multidrug resistance protein, cMRP/MRP2, a novel conjugate export pump expressed in the apical membrane of hepatocytes. Adv Enzyme Regul 37: 321-333, 1997.
48. 48. Kool M, de Haas M, Scheffer GL, Scheper RJ, van Eijk MJ, Juijn JA, Baas F and Borst P, Analysis of expression of cMOAT (MRP2), MRP3, MRP4, and MRP5, homologues of the multidrug resistance-associated protein gene (MRP1), in human cancer cell lines. Cancer Res 57: 3537-3547, 1997.
49. 1 confers resistance to alkylating agents. Proc Natl Acad Sci USA 87: 2443-2447, 1990.
50. 50. Ishikawa T, The ATP-dependent glutathione S-conjugate export pump, Trends Biochem Sci 17: 463-468, 1992.
51. 1 and its glutathione conjugates by the product of the multidrug resistance protein (MRP) gene. Mol Pharmacol 51: 1034-1041, 1997.
52. 52. Versantvoort CH, Broxterman HJ, Bagrij T, Scheper RJ and Twentyman PR, Regulation by glutathione of drug transport in multidrug-resistant human lung tumour cell lines overexpressing multidrug resistance-associated protein. Br J Cancer 72: 82-89, 1995.
53. 53. Zaman GJR, Lankelma J, van Tellingen O, Beijnen J, Dekker H, Paulusma C, Oude Elferink RPJ, Baas F and Borst P, Role of glutathione in the export of compounds from cells by the multidrug resistance-associated protein. Proc Natl Acad Sci USA 92: 7690-7694, 1995.
54. 54. Meister A, Methods for the selective modification of glutathione metabolism and study of glutathione transport. Methods Enzymol 113: 571-585, 1985.
55. 55. Kaplowitz N, Femandez-Checa JC, Kannan R, Garcia-Ruiz C, Ookhtens M and Yi JR, GSH transporters: Molecular characterization and role in GSH homeostasis. Biol Chem Hoppe Seyler 377: 267-273, 1996.
56. 56. Vanhoefer U, Cao S, Minderman H, Toth K, Skenderis BS, Slovak ML and Rustum YM, D,L-Buthionine-(S,R)-sulfoximine potentiates in vivo the therapeutic efficacy of doxorubicin against multidrug resistance protein-expressing tumors. Clin Cancer Res 2: 1961-1968, 1996.
57. 57. Taguchi Y, Yoshida A, Takada Y, Komano T and Ueda K, Anti-cancer drugs and glutathione stimulate vanadate-induced trapping of nucleotide in multidrug resistance-associated protein (MRP). FEBS Lett 401: 11-14, 1997.
58. 58. Kuo MT, Bao J, Furuichi M, Yamane Y, Gomi A, Savaraj N, Masuzawa T and Ishikawa T, Frequent coexpression of MRP/ GS-X pump and γ-glutamylcysteine synthetase mRNA in drug-resistant cells, untreated tumor cells, and normal mouse tissues. Biochem Pharmacol 55: 605-615, 1998.